Accéder au contenu
Merck

Unscheduled HDAC4 repressive activity in human fibroblasts triggers TP53-dependent senescence and favors cell transformation.

Molecular oncology (2018-10-14)
Harikrishnareddy Paluvai, Eros Di Giorgio, Claudio Brancolini
RÉSUMÉ

Expression of the class IIa HDACs is frequently altered in different human cancers. In mouse models these transcriptional repressors can trigger transformation, acting as bona fide oncogenes. Whether class IIa HDACs also exhibit transforming activities in human cells is currently unknown. We infected primary human fibroblasts with retroviruses to investigate the transforming activity of HDAC4 in cooperation with well-known oncogenes. We have discovered that HDAC4 triple mutant (S246A, S467A, S632A) (HDAC4-TM), a nuclear resident version of the deacetylase, triggers TP53 stabilization and OIS (oncogene-induced senescence). Unlike RAS, HDAC4-induced OIS was TP53-dependent and characterized by rapid cell cycle arrest and accumulation of an unusual pattern of γH2AX-positive foci. The inactivation of both TP53 and of the retinoblastoma (pRb) tumor suppressors, as induced by the viral oncogenes large and small T of SV40, triggers anchorage-independent growth in RAS, HDAC4-TM and, to a lesser extent, in HDAC4-wild type (WT)-expressing cells. Our results suggest an oncogenic function of class IIa HDACs in human cells, and justify further efforts to discover and evaluate isoform-specific inhibitors of these epigenetic regulators from a therapeutic perspective.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Anti-Vinculin Mouse mAb (V284 or VLN01), liquid, Calbiochem®, from mouse